Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia

Gene Therapy

Volumn 5, Issue 1, 1998, Pages 40-49

  Monahan, P E ^a   Samulski, R J ^a   Tazelaar, J ^a   Xiao, X ^a   Nichols, T C ^a,b   Bellinger, D A ^a,b   Read, M S ^a,b   Walsh, C E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Canine; Factor IX; Gene transfer; Hemophilia B; Muscle; Parvovirus

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOG; EXPRESSION VECTOR; FIBROBLAST CULTURE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEMOPHILIA B; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MUSCLE CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS; CYTOMEGALOVIRUS; DNA VIRUSES; PARVOVIRUS;

EID: 0031983639     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300548     Document Type: Article

References (39)

1. Roberts, HR, Lozier, JN. Clinical aspects and therapy for hemophilia B. In: Hoffman R et al (eds). Hematology: Basic Principles and Practice. Churchill-Livingstone: New York, 1995, pp 1678-1685.
2. Samulski RJ. Adeno-associated viral vectors. In: Vos J-MH (ed). Viruses in Human Gene Therapy. Chapman and Hall: London, 1995, pp 53-76.
3. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle of immunocompetent mice by adeno-associated virus vector. J Viral 1996; 70: 8098-8108.
4. Lozier JN et al. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DMA complexes. Hum Gene Ther 1994; 5: 313-322.
5. Roman M et al. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat Cell Mol Genet 1992; 18: 247-258.
6. Yao S-N, Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts Proc Natl Acad Sci USA 1992; 89: 3357-3361.
7. Dhawan J et al. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 1991; 254: 1509-1512.
8. Kessler PD et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996, 93, 14082-14087.
9. Levy MY, Barren LG, Meyer KB, Szoka Jr FC. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Therapy 1996; 3: 201-211.
10. Xing Z et al. Adenoviral vector-mediated interleukin-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia. Gene Therapy 1997; 4: 140-149.
11. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997; 8: 659-669.
12. Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306-312.
13. Brinkhous KM et al. Recombinant human factor IX: replacement therapy, prophylaxis and pharmacokinetics in canine hemophilia B. Blood 1996; 88: 2603-2610.
14. Keith Jr JC et al. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 1994; 73: 101-105.
15. Kurachi S, Hitomi Y, Furukawa M, Kurachi K. Role of intron 1 expression of the human factor IX gene. J Biol Chem 1995; 270: 5276-5281.
16. Evans JP et al. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 1989; 86: 10095-10099
17. Dai Y, Roman M, Naviaux RK, Verma IM. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo Proc Natl Acad Sci USA 1992; 89: 10892-10895.
18. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
19. Miller G et al. Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modeling gene therapy for haemophilia. Gene Therapy 1995; 2: 736-742.
20. Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473-482.
21. Barr D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
22. Herzog RW et al Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804-5809.
23. Cheung WF et al. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996; 93: 11068-11073.
24. Axelrod JH, Read MS, Brinkhous KM, Verma IM. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc Natl Acad Sci USA 1990; 87: 5173-5177.
25. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
26. Fisher KJ et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
27. Alexander IE, Russell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adenoassociated virus vectors. J Virol 1994; 68: 8282-8287.
28. Alexander IE, Russell DW, Spence AM, Miller AD. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum Gene Ther 1996; 7: 841-850.
29. Rando T, Blau H. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275-1287.
30. Ascadi G et al. Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Gene Therapy 1994; 1: 338-340.
31. Ascadi G, et al Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther 1996; 7: 129-140.
32. Yang Y, Haecker SE, Su Q, Wilson JM. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle Hum Mol Genet 1996; 5: 1703-1712.
33. McCoy RD et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther 1995; 6: 1553-1560.
34. Yao S-N et al. Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci USA 1991; 88: 8101-8105.
35. Zolotukhm S et al. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996; 70: 4646-4654.
36. Anonymous, Coagulation Procedures. Ortho Diagnostics. Raritan, NJ, 1968, p 16.
37. Li J, Samulski RJ, Xiao X. Role for highly regulated Rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236-5243.
38. Samulski RJS, Chang LS, Shenk T Helper-free stocks of recombinant adeno-associated viruses; normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
39. Brinkhous KM, Landen CN, Read MS. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 1993; 82 (Suppl 1): 592a (Abstr. 2352).